Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.42 |
| ▸ | SRC | P12931 | 8/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.42 |
| ▸ | PRKDC | P78527 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HCK | P08631 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651681 | 1.00 | PIK3CG (0.55) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL29651709 | 0.92 | PIK3CG (0.55) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL10916 | 0.92 | PIK3CG (0.55) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL10856 | 0.86 | PIK3CD (0.48) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL29651601 | 0.86 | PIK3CD (0.48) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL29651716 | 0.85 | BTK (0.49) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL11097 | 0.85 | BTK (0.49) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL29651648 | 0.84 | PIK3CD (0.49) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL11135 | 0.84 | PIK3CD (0.49) | PIK3CGPIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL131144 | 0.84 | PIK3CD (0.54) | PIK3CGPIK3CDSRCPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | claimed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | claimed |
| CN-117222413-A | Methods and combinations for treating tumors | 同润生物医药(上海)有限公司 | 2023-12-12 | — | — | CN | claimed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| EP-2496567-B1 | NOVEL BENZOPYRAN KINASE MODULATORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-07-12 | — | — | EP | claimed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
| CN-117222413-A | Methods and combinations for treating tumors | 同润生物医药(上海)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CG 99/4885PIK3CD 70/4885SRC 314/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CG 99/4885PIK3CD 70/4885SRC 314/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PIK3CG 126/4885PIK3CD 103/4885SRC 110/4885 |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885SRC 1363/4885 |
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | PDCD1, PDCD1LG2, CD274 | PIK3CG 221/4885PIK3CD 116/4885SRC 334/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CG 99/4885PIK3CD 70/4885SRC 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.